Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression.

Seminars in oncology - 1 Feb 2012

Ernst Thomas, Hochhaus Andreas

Abstract excerpt

The introduction of the tyrosine kinase inhibitors (TKIs) imatinib, dasatinib, and nilotinib has dramatically improved the treatment of chronic myeloid leukemia (CML). However, a minority of CML patients in chronic phase (CP) and a substantial proportion of patients in advanced phase are either initially refractory to TKIs or eventually develop resistance. Rates of resistance and relapse directly correlate with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Progression
Share to Fusion Proteins, bcr-abl
Share to ABL1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BCR gene

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Source

Identifiers

PMID: 22289492
DOI: 10.1053/j.seminoncol.2011.11.002

Genes

ABL1
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression.PMID 22289492Read ↗

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.Semantic proximity Read ↗

Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An UpdateSemantic proximity Read ↗

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.Semantic proximity Read ↗

Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.Semantic proximity Read ↗

Molecular biology of bcr-abl1–positive chronic myeloid leukemiaSemantic proximity Read ↗

Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.Semantic proximity Read ↗

Genetic landscape of chronic myeloid leukemia.Semantic proximity Read ↗

Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.Semantic proximity Read ↗

Therapeutic Targets for Overcoming BCR::ABL1 Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.Semantic proximity Read ↗

Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemiaSemantic proximity Read ↗

New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib ResistanceSemantic proximity Read ↗

Advances in Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: The Evolving Role of Bcr–Abl Mutations and Mutational AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.